NCT04400695 - A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 | Biotech Hunter

Enrollment

366

Participants

Timeline

Start Date

September 29, 2020

Primary Completion Date

June 30, 2024

Study Completion Date

December 30, 2024

Conditions

Breast Cancer

Interventions

DRUG

RC48-ADC

RC48-ADC 2.0mg / kg, intravenous drip, once every 2 weeks

DRUG

Paclitaxel Injection

Administered according to label, as one option for Physician's Choice (determined before randomization)

DRUG

Docetaxel Injection

Administered according to label, as one option for Physician's Choice (determined before randomization)

DRUG

Vinorelbine Tartrate Injection

Administered according to label, as one option for Physician's Choice (determined before randomization)

DRUG

Capecitabine Tablets

Administered according to label, as one option for Physician's Choice (determined before randomization)

Trial Locations (1)

RECRUITING

Oncology Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors

lead

RemeGen Co., Ltd.

INDUSTRY